Biopolymer mitralheart valve feasibility study provides hope for mitral disease patients
The first-in-human use of Foldax’s biopolymer Tria™ heart valve as a replacement for a diseased mitral valve has shown positive results. The first case was performed by David Heimansohn, MD, at Ascension St. Vincent Hospital, Indianapolis, as part of a U.S. early feasibility research study.